Browsing Tag
Uplizna
5 posts
Amgen (NASDAQ: AMGN) wins EC approval for UPLIZNA in generalized myasthenia gravis market
European Commission clears Amgen Inc.’s UPLIZNA for generalized myasthenia gravis. Discover what this means for competition, pricing, and the autoimmune drug market.
Can UPLIZNA transform gMG treatment? Amgen’s FDA win sets new benchmark for antibody-positive patients
Discover how Amgen’s UPLIZNA is redefining generalized myasthenia gravis treatment after FDA approval. Find out what this means for patients and investors.
Amgen to acquire Irish biopharma company Horizon Therapeutics for $28bn
Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise…
Horizon Therapeutics announces $3.05bn acquisition of Viela Bio to expand rare disease pipeline
In a major move to strengthen its leadership in rare diseases, Horizon Therapeutics, an Irish biopharmaceutical company, has…
US biotech company Viela Bio bags Uplizna FDA approval for NMOSD
Uplizna FDA approval : US biotech company Viela Bio has secured approval from the US Food and Drug…